metaEvidence - study list


	Study	study type RCT OBS RCT + OBS	Pathology	T1	T0	Patients	sample sizes	ROB	Results
mCRC - 1st line (L1) metastatic/advanced - colorectal cancer (mCRC) mCRC - 1st line (L1)
versus Standard of Care (SoC)
	pembrolizumab alone
	KEYNOTE-177, 2020 N Engl J Med. 2020 Dec 3;383(23):2207-2218. Lancet Oncol 2021 Apr 1;S1470-2045(21)00064-4. Lancet Oncol 2022; 23:659-670-. NCT02563002	RCT	mCRC - 1st line (L1)	Pembrolizumab	chemotherapy FOLFIRI or FOLFOX plus targeted therapy	treatment-naïve U.S. patients with microsatellite instability-high (MSI-H) and/or mismatch repair-deficient (dMMR) metastatic colorectal cancer (mCRC)	153 / 154	some concern	conclusif	demonstrated 40 % decrease in progression or deaths (PFS) (PE) this study demonstrated a doubling in progression-free survival (PFS) with pembrolizumab versus standard chemotherapy in patients with newly diagnosed MSI-H mCRC leading to FDA approval for pembrolizumab in first line treatment of patients with unresectable or metastatic MSI-H/dMMR CRC
mCRC - 2nd line (L2) metastatic/advanced - colorectal cancer (mCRC) mCRC - 2nd line (L2)
versus BSC
	durvalumab plus tremelimumab
	CO.26 study, 2020 JAMA Oncol 2020 Jun 1;6(6):831-838. NCT02870920	RCT	mCRC - 2nd line (L2)	durvalumab plus tremelimumab and BSC	BSC	Patients With Advanced Colorectal Adenocarcinoma Refractory to Standard Therapies	119 / 61	some concern	inconclusive	suggested 28 % decrease in deaths (OS) (PE)
versus regorafenib
	atezolizumab alone
	IMblaze-370 (A ; all population), 2019 Lancet Oncol. 2019; 20:849-861 NCT02788279	RCT	mCRC - 2nd line (L2)	atezolizumab monotherapy	regorafenib	patients with unresectable locally advanced or metastatic colorectal cancer and disease progression on or intolerance to at least two previous systemic chemotherapy regimens were enrolled.	90 / 90	some concern	inconclusive	inconclusive 0 % increase in deaths (OS) (PE)
	atezolizumab plus cometinib
	IMblaze-370 (AC ; all population), 2019 Lancet Oncol. 2019; 20:849-861 NCT02788279	RCT	mCRC - 2nd line (L2)	atezolizumab plus cometinib	regorafenib	patients with unresectable locally advanced or metastatic colorectal cancer with disease progression on or intolerance to at least two previous systemic chemotherapy regimens were enrolled.	183 / 90	some concern	inconclusive	inconclusive 0 % increase in deaths (OS) (PE)